Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

utcomes measure used in the successful Phase 2 meniscectomy trial.

OMS302 will be evaluated for safety and efficacy in patients undergoing intra-ocular lens replacement surgery. The trials will enroll both cataract surgery and refractive lens exchange patients. This clinical program will involve two randomized, double-blind, placebo-controlled, multicenter trials. The first trial will be conducted in North America and data are expected in the first half of 2012.  Omeros will initiate the second trial in Europe following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

Omeros' OMS103HP Program

OMS103HP is Omeros' PharmacoSurgery™ product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), each with well-known safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles.

In a Phase 2 clinical trial that evaluated OMS103HP in patients undergoing partial meniscectomy surgery, OMS103HP provided clinically meaningful and significantly greater efficacy than vehicle as measured by patient-reported functional scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), passive knee flexion and visual analog scale pain scores. The patient-
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... May 18, 2011 The Consumer Healthcare Products ... acetaminophen medicines for children, applauds the U.S. Food ... and caregivers give their children the right amount ... Committee and Pediatric Advisory Committee recommended enhancing the ...
... Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... neuro-otologic, vestibular and neurological testing, said today that ... control and analysis software. Clinical specialists ... conduct vestibular, oculomotor and optokinetic tests to detect ...
Cached Medicine Technology:OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 2OTC Industry Supports FDA Advisory Committee Recommendations on New Dosing Instructions 3Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software 2
(Date:7/10/2014)... The benefits of medical imaging far outweigh the risks ... Way, with The Right Radiation Dose. However, overuse and ... Clinic is leading a collaborative effort to ensure a ... online in the Journal of Patient Safety , ... Commission, the Intersociety Accreditation Commission, and the Centers for ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... localized prostate cancer were more likely to be ... effective treatments and survived for shorter times than ... UCLA study has found. , The negative outcomes ... as bias against the mentally ill, depression,s impact ... of investment in his general health and disinterest ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2
... is,a leader in serving people who are visually impaired -- ... People who are legally blind can function and lead effectively ... The news that Lt. Gov. Paterson will become Governor ... people with vision loss can,achieve great heights., As I ...
... the finding shouldn,t keep physicians from using Avastin, researchers say ... cancer drug Avastin can cause kidney damage by doing what ... study shows. , Avastin, whose generic name is bevacizumab, is ... attack cancers by cutting off their blood supply. It does ...
... 12 As previously,disclosed in its Form 8-K filed ... NHWK ) announced that Ernest G. Ludy has resigned,from ... of Directors for,personal reasons. As a result of such ... with Nasdaq Marketplace Rule,4350(d)(2) -- which requires the company,s ...
... Omega T, an Omega 3 and Turmeric ... ... makers,of Conquer HA(TM), introduce the latest addition to their family of joint,relief ... T,is powerful natural anti-inflammatory formula containing Omega 3 and,Turmeric for double strength ...
... 2008) The American Society of Nephrology (ASN), in ... American Society of Pediatric Nephrology (ASPN), will celebrate the ... and patient advocates from across the nation will hold ... raise awareness of chronic kidney disease (CKD) as a ...
... observed that cancer cells perform energy metabolism in a way ... later, this observation was exploited by clinicians to better visualize ... not been known exactly how tumor cells perform this alternate ... essential for tumor growth. , Now, two papers appearing in ...
Cached Medicine News:Health News:Doctors See How Cancer Drug Can Damage Kidneys 2Health News:Doctors See How Cancer Drug Can Damage Kidneys 3Health News:Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market 2Health News:The Makers of Conquer HA(TM) Launch All-Natural Double Strength Anti- Inflammatory Formula 2Health News:ASN members visit Capitol Hill to promote World Kidney Day and CKD awareness 2Health News:Study helps explain fundamental process of tumor growth 2Health News:Study helps explain fundamental process of tumor growth 3
The base of the staple is round and threaded to enable screwing onto the stapler. The base also has spikes. The legs of the staple are contoured to prevent the staple from backing out....
The staple fixation system provides a simple means of attaching tissue to bone....
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
Medicine Products: